Clarient's Ovotax test may help improve patients’ response to taxane therapy

[News]

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that data from a new study shows that Clarient's Ovotax™ assay may effectively predict which ovarian cancer patients will respond favorably to taxane therapy and could, therefore, be spared the potential side effects of this rigorous and sometimes toxic chemotherapy agent.

More... (http://www.news-medical.net/news/20100317/Clarients-Ovotax-test-may-help-improve-patientse28099-response-to-taxane-therapy.aspx)